ArticleIrish journal of medical science2026
Albumin-Bilirubin and Platelet-Albumin-Bilirubin scores as predictors of all-cause long-term mortality in intermediate-high-risk pulmonary embolism.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association between albumin-bilirubin (ALBI) score and all-cause mortality in critically ill patients with pulmonary embolism: a cohort study based on the MIMIC-IV database.Journal of thoracic disease · 2026Article
- Evaluation of the relationship between thrombus burden, inflammation indices, and prognosis in central and peripheral pulmonary embolism.Thrombosis journal · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntermediate-high-risk pulmonary embolism (PE) carries substantial early and long-term mortality, yet validated biomarkers for risk stratification remain limited. Liver function-based indices, such as the albumin-bilirubin (ALBI) and platelet-albumin-bilirubin (PALBI) scores, may capture systemic compromise related to venous congestion and impaired hepatic perfusion, but their prognostic role in PE has not been established.
methodsWe conducted a single-center, retrospective cohort study of 274 patients with intermediate-high-risk acute PE admitted between January 2023 and March 2024. Baseline demographic, clinical, echocardiographic, and laboratory parameters were collected, and ALBI and PALBI scores were calculated within 24 h of admission. The primary endpoint was long-term all-cause mortality.
resultsDuring a median follow-up of 18 months, 65 patients (23.7%) died. Non-survivors had significantly higher ALBI (-2.53 vs. -3.13, p < 0.001) and PALBI (-2.75 vs. -3.04, p < 0.001) scores. Both indices independently predicted mortality after multivariable adjustment. ALBI (HR 2.821, 95% CI 1.161-4.792, p < 0.001) and PALBI (HR 1.837, 95% CI 1.093-3.086, p = 0.022) were strong prognostic markers. ROC analyses demonstrated discriminative accuracy for both indices, with an AUC of 0.764 for ALBI and 0.682 for PALBI. Survival analyses showed stepwise mortality increases across score tertiles (log-rank p < 0.001).
conclusionsThis study is the first to demonstrate that ALBI and PALBI scores provide independent and incremental prognostic value for long-term mortality in patients with intermediate-to-high-risk PE. These indices represent simple, cost-effective tools that may enhance current risk stratification frameworks. External validation in larger cohorts is warranted.
Indexed as
Identifiers
41348424What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.